Why a DNA data breach is much worse than a credit card leak
By Angela Chen,
The Verge
| 06. 06. 2018
This week, DNA testing service MyHeritage revealed that hackers had breached 92 million of its accounts. Though the hackers only accessed encrypted emails and passwords — so they never reached the actual genetic data — there’s no question that this type of hack will happen more frequently as consumer genetic testing becomes more and more popular. So why would hackers want DNA information specifically? And what are the implications of a big DNA breach?
One simple reason is that hackers might want to sell DNA data back for ransom, says Giovanni Vigna, a professor of computer science at UC Santa Barbara and co-founder of cybersecurity company Lastline. Hackers could threaten to revoke access or post the sensitive information online if not given money; one Indiana hospital paid $55,000 to hackers for this very reason. But there are reasons genetic data specifically could be lucrative. “This data could be sold on the down-low or monetized to insurance companies,” Vigna adds. “You can imagine the consequences: One day, I might apply for a long-term loan and get...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...